The bull case is that large pharma patent cliffs create ongoing demand for external innovation, especially when public biotech valuations are depressed.
♥ 0 Thanks from members
Peer Perspective on Biotech Funding Cycles & Pharma M&A
Posted 6/30/2026
Posted 6/30/2026
The bull case is that large pharma patent cliffs create ongoing demand for external innovation, especially when public biotech valuations are depressed.